What is HC Wainwright’s Estimate for BLFS Q1 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of BioLife Solutions in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst Y. Chen forecasts that the medical equipment provider will post earnings of ($0.10) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.41) EPS.

BLFS has been the subject of a number of other research reports. Northland Securities boosted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Craig Hallum increased their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, TD Cowen boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.50.

BioLife Solutions Trading Up 11.5 %

BLFS stock opened at $25.01 on Wednesday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -23.59 and a beta of 1.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a fifty day moving average price of $23.96 and a two-hundred day moving average price of $22.88. BioLife Solutions has a one year low of $11.91 and a one year high of $28.88.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions during the 3rd quarter worth $28,000. 1620 Investment Advisors Inc. acquired a new stake in BioLife Solutions during the 2nd quarter worth about $35,000. Isthmus Partners LLC grew its stake in BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 42,265 shares during the period. Quest Partners LLC acquired a new stake in BioLife Solutions in the third quarter worth $57,000. Finally, GAMMA Investing LLC increased its stake in BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Activity

In other news, EVP Aby J. Mathew sold 17,604 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the completion of the transaction, the executive vice president now directly owns 284,442 shares in the company, valued at approximately $5,703,062.10. The trade was a 5.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the sale, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. This represents a 2.61 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 69,644 shares of company stock worth $1,527,503. 2.20% of the stock is currently owned by company insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.